Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control

Weight Change and Metabolic Effects of Asenapine in Patients With Schizophrenia and Bipolar Disorder

(2014) David E. Kemp et al.   JOURNAL OF CLINICAL PSYCHIATRY

Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle-income countries

(2012) Antonio Lora et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

A Randomized Placebo-Controlled Trial of Asenapine for the Prevention of Relapse of Schizophrenia After Long-Term Treatment

(2011) John M. Kane et al.   JOURNAL OF CLINICAL PSYCHIATRY

Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia

(2010) John M. Kane et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Long-Term Assessment of Asenapine vs. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder

(2010) J. Schoemaker et al.   PHARMACOPSYCHIATRY

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

(2008) M. Shahid et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Schizophrenia, “Just the Facts”: What we know in 2008

(2008) Rajiv Tandon et al.   SCHIZOPHRENIA RESEARCH